Motley Fool
Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
📊
AI Sentiment
Positive
6/10
- Home
- SRRK
as of 02-26-2026 3:37pm EST
$44.60
$2.37
-5.05%
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 4.9B | IPO Year: | 2018 |
| Target Price: | $51.20 | AVG Volume (30 days): | 757.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.54 | EPS Growth: | -24.12 |
| 52 Week Low/High: | $22.71 - $49.82 | Next Earning Date: | 04-10-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 21831.23% |
| P/E Ratio: | -18.49 | Index: | N/A |
| Free Cash Flow: | -201047000.0 | FCF Growth: | N/A |
AI-Powered SRRK Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 69.13%
69.13%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Scholar Rock Holding Corporation (SRRK)
Qatanani Mo
Sell
CHIEF SCIENTIFIC OFFICER
SRRK Feb 23, 2026
Avg Cost/Share
$47.76
Shares
8,484
Total Value
$399,350.71
Owned After
98,445
Qatanani Mo
Sell
CHIEF SCIENTIFIC OFFICER
SRRK Feb 17, 2026
Avg Cost/Share
$46.53
Shares
7,989
Total Value
$371,713.79
Owned After
98,445
SEC Form 4
Parlavecchio Caryn
Sell
CHRO
SRRK Feb 17, 2026
Avg Cost/Share
$46.53
Shares
9,035
Total Value
$420,382.29
Owned After
169,087
SEC Form 4
Marantz Jing L.
Sell
CHIEF MEDICAL OFFICER
SRRK Feb 17, 2026
Avg Cost/Share
$46.53
Shares
4,157
Total Value
$193,417.73
Owned After
126,012
SEC Form 4
Qatanani Mo
Sell
CHIEF SCIENTIFIC OFFICER
SRRK Jan 22, 2026
Avg Cost/Share
$46.36
Shares
14,898
Total Value
$695,937.54
Owned After
98,445
Qatanani Mo
Sell
CHIEF SCIENTIFIC OFFICER
SRRK Jan 16, 2026
Avg Cost/Share
$44.48
Shares
8,406
Total Value
$373,879.55
Owned After
98,445
SEC Form 4
Parlavecchio Caryn
Sell
CHRO
SRRK Jan 16, 2026
Avg Cost/Share
$44.48
Shares
6,600
Total Value
$293,552.82
Owned After
169,087
SEC Form 4
Marantz Jing L.
Sell
CHIEF MEDICAL OFFICER
SRRK Jan 16, 2026
Avg Cost/Share
$44.48
Shares
5,798
Total Value
$257,881.70
Owned After
126,012
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Feb 23, 2026 | Sell | $47.76 | 8,484 | $399,350.71 | 98,445 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Feb 17, 2026 | Sell | $46.53 | 7,989 | $371,713.79 | 98,445 | |
| Parlavecchio Caryn | SRRK | CHRO | Feb 17, 2026 | Sell | $46.53 | 9,035 | $420,382.29 | 169,087 | |
| Ho Junlin | SRRK | GENERAL COUNSEL | Feb 17, 2026 | Sell | $46.53 | 9,580 | $445,740.16 | 241,545 | |
| Marantz Jing L. | SRRK | CHIEF MEDICAL OFFICER | Feb 17, 2026 | Sell | $46.53 | 4,157 | $193,417.73 | 126,012 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Jan 22, 2026 | Sell | $46.36 | 14,898 | $695,937.54 | 98,445 | |
| Qatanani Mo | SRRK | CHIEF SCIENTIFIC OFFICER | Jan 16, 2026 | Sell | $44.48 | 8,406 | $373,879.55 | 98,445 | |
| Parlavecchio Caryn | SRRK | CHRO | Jan 16, 2026 | Sell | $44.48 | 6,600 | $293,552.82 | 169,087 | |
| Ho Junlin | SRRK | GENERAL COUNSEL | Jan 16, 2026 | Sell | $44.48 | 8,016 | $356,533.24 | 241,545 | |
| Marantz Jing L. | SRRK | CHIEF MEDICAL OFFICER | Jan 16, 2026 | Sell | $44.48 | 5,798 | $257,881.70 | 126,012 |
Latest Scholar Rock Holding Corporation News
SRRK Breaking Stock News: Dive into SRRK Ticker-Specific Updates for Smart Investing
Motley Fool
Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year
âž–
AI Sentiment
Neutral
4/10
Motley Fool
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
📈
AI Sentiment
Highly Positive
9/10
Motley Fool
Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26%
📈
AI Sentiment
Highly Positive
8/10
Compare SRRK vs Leading Stocks
See how SRRK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SRRK Scholar Rock Holding Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.